study,trt,class,n,r
agger 2017,placebo,placebo,59,10
agger 2017,imipramine low,tca,65,32
ahmed 2016,placebo,placebo,15,5
ahmed 2016,milnacipran standard,snri,15,10
allen 2014,placebo,placebo,90,68
allen 2014,desvenlafaxine standard,snri,63,47
allen 2014,desvenlafaxine high,snri,87,65
allen 2014,desvenlafaxine high,snri,99,82
allen 2014,desvenlafaxine high,snri,69,63
allen 2017,placebo,placebo,130,106
allen 2017,desvenlafaxine standard,snri,136,123
allen 2017,desvenlafaxine high,snri,139,122
allen 2017,desvenlafaxine high,snri,142,122
allen 2017,desvenlafaxine high,snri,149,136
ang 2013,cognitive behavioural therapy ,nonad,19,3
ang 2013,cognitive behavioral therapy and milnacipran standard,snri,20,9
ang 2013,milnacipran standard,snri,19,8
arnold 2004,placebo,placebo,103,77
arnold 2004,duloxetine high,snri,104,94
arnold 2005,placebo,placebo,120,95
arnold 2005,duloxetine standard,snri,118,109
arnold 2005,duloxetine high,snri,116,105
arnold 2010: 1,placebo,placebo,133,76
arnold 2010: 1,esreboxetine unable to be categorised,snri,134,96
arnold 2010: 2,placebo,placebo,509,382
arnold 2010: 2,milnacipran standard,snri,516,434
arnold 2010: 3,placebo,placebo,267,191
arnold 2010: 3,duloxetine high,snri,263,218
arnold 2012: 1,placebo,placebo,153,79
arnold 2012: 1,duloxetine low,snri,155,100
arnold 2012: 2,placebo,placebo,277,85
arnold 2012: 2,esreboxetine standard,snri,274,158
arnold 2012: 2,esreboxetine standard,snri,282,157
arnold 2012: 2,esreboxetine high,snri,107,62
atkinson 1998,placebo,placebo,29,29
atkinson 1998,nortriptyline unable to be categorised,tca,28,28
atkinson 1999,maprotiline low,teca,33,18
atkinson 1999,paroxetine unable to be categorised,ssri,34,20
atkinson 1999,placebo,placebo,36,31
bateman 2011,milnacipran unable to be categorised,snri,85,63
bateman 2011,placebo,placebo,21,16
bird 2000,paroxetine unable to be categorised,ssri,94,53
bird 2000,amitriptyline high,tca,96,65
branco 2010,placebo,placebo,446,331
branco 2010,milnacipran high,snri,431,363
cannon 1994,placebo,placebo,20,11
cannon 1994,clonidine ,nonad,20,14
cannon 1994,imipramine low,tca,20,15
cardenas 2002,placebo,placebo,40,36
cardenas 2002,amitriptyline unable to be categorised,tca,44,43
carette 1986,placebo,placebo,33,4
carette 1986,amitriptyline unable to be categorised,tca,27,19
carette 1994,placebo,placebo,84,52
carette 1994,amitriptyline standard,tca,82,78
carette 1994,cyclobenzaprine ,nonad,42,41
caruso 1987,placebo,placebo,30,6
caruso 1987,dothiepin standard,tca,30,18
chappell 2008,placebo,placebo,168,137
chappell 2008,duloxetine high,snri,162,145
chappell 2009: 1,duloxetine standard,snri,104,89
chappell 2009: 1,duloxetine high,snri,203,179
chappell 2009: 2,placebo,placebo,120,49
chappell 2009: 2,duloxetine high,snri,111,55
chappell 2011,placebo,placebo,128,42
chappell 2011,duloxetine high,snri,128,65
clauw 2008,placebo,placebo,401,317
clauw 2008,milnacipran standard,snri,399,358
clauw 2008,milnacipran high,snri,396,346
dezanette 2014,melatonin ,nonad,21,10
dezanette 2014,amitriptyline standard,tca,21,18
dezanette 2014,melatonin + amitriptyline standard,tca,21,9
enomoto 2018,pregabalin ,nonad,151,54
enomoto 2018,duloxetine low,snri,152,45
enteshari-moghaddam 2019,acetaminophen ,nonad,50,0
enteshari-moghaddam 2019,duloxetine standard,snri,50,8
enteshari-moghaddam 2019,gabapentin ,nonad,50,9
foster 2010: 2,placebo,placebo,136,98
foster 2010: 2,amitriptyline standard,tca,135,119
frakes 2011,placebo,placebo,260,130
frakes 2011,duloxetine high,snri,264,167
gao 2010,placebo,placebo,109,78
gao 2010,duloxetine high,snri,106,86
gao 2015,placebo,placebo,202,72
gao 2015,duloxetine standard,snri,202,94
gillving 2021,terbutaline ,nonad,51,27
gillving 2021,imipramine standard,tca,51,38
gillving 2021,placebo,placebo,51,17
ginsberg 1996,placebo,placebo,25,0
ginsberg 1996,amitriptyline standard,tca,26,7
ginsberg 1998,placebo,placebo,44,16
ginsberg 1998,pirlindole low,maoi_rev,45,18
goldman 2010,placebo,placebo,59,13
goldman 2010,amitriptyline standard,tca,59,18
gould 2020,placebo,placebo,33,6
gould 2020,desipramine low,tca,38,12
gould 2020,cognitive behavioural therapy ,nonad,34,8
gould 2020,desipramine + cognitive behavioural therapy low,tca,37,7
hannonen 1998,moclobemide high,maoi_rev,43,33
hannonen 1998,amitriptyline standard,tca,42,31
hannonen 1998,placebo,placebo,45,36
holbech 2015,placebo,placebo,69,24
holbech 2015,pregabalin ,nonad,69,25
holbech 2015,imipramine standard,tca,70,30
holbech 2015,pregabalin + imipramine standard,tca,69,40
hudson 2021,nortriptyline low,snri,99,97
hudson 2021,placebo,placebo,102,88
joharchi 2019,duloxetine low,snri,90,67
joharchi 2019,pregabalin ,nonad,90,34
jose 2007,lamotrigine ,nonad,46,33
jose 2007,amitriptyline unable to be categorised,tca,46,11
keefe 2010,placebo,placebo,28,5
keefe 2010,sertraline high,ssri,30,10
keefe 2010,coping skills training ,nonad,29,7
keefe 2010,coping skills training + sertraline high,ssri,28,7
khoromi 2007,placebo,placebo,28,14
khoromi 2007,morphine ,nonad,28,26
khoromi 2007,nortriptyline standard,tca,28,19
khoromi 2007,morphine + nortriptyline low,tca,28,25
kim 2013,placebo,placebo,20,18
kim 2013,milnacipran unable to be categorised,snri,20,12
lee 2010,placebo,placebo,22,3
lee 2010,venlafaxine low,snri,21,11
lee 2016,placebo,placebo,41,8
lee 2016,milnacipran standard,snri,41,17
leijon 1989,placebo,placebo,15,7
leijon 1989,amitriptyline standard,tca,15,14
leijon 1989,carbamazepine ,nonad,14,12
lipone 2020,gabapentin ,nonad,48,20
lipone 2020,trazodone + gabapentin low,sari,43,27
lipone 2020,trazodone + gabapentin low,sari,51,21
majdinasab 2019,gabapentin ,nonad,52,9
majdinasab 2019,duloxetine low,snri,52,2
max 1988,placebo,placebo,41,30
max 1988,amitriptyline standard,tca,41,36
max 1988,lorazepam ,nonad,41,36
max 1992,desipramine standard,tca,54,30
max 1992,amitriptyline high,tca,54,31
mease 2009,placebo,placebo,223,190
mease 2009,milnacipran standard,snri,224,186
mease 2009,milnacipran high,snri,441,400
miki 2016,placebo,placebo,215,122
miki 2016,mirtazapine standard,nassa,215,148
morello 1999,gabapentin ,nonad,25,18
morello 1999,amitriptyline standard,tca,25,17
murakami 2015,placebo,placebo,197,123
murakami 2015,duloxetine standard,snri,196,148
nabi 2021,tens ,nonad,30,0
nabi 2021,duloxetine standard,snri,30,18
natelson 2015,placebo,placebo,17,1
natelson 2015,milnacipran standard,snri,17,2
nct 2011,placebo,placebo,17,0
nct 2011,milnacipran high,snri,29,9
nct 2003,cognitive behavioural therapy ,nonad,38,24
nct 2003,nortriptyline + cognitive behavioural therapy unable to be categorised,tca,41,32
nct 2003,disease management ,nonad,24,15
nct 2003,nortriptyline + disease management unable to be categorised,tca,37,21
nct 2010,placebo,placebo,20,10
nct 2010,milnacipran high,snri,20,14
otto 2008,placebo,placebo,41,18
otto 2008,escitalopram high,ssri,41,21
patkar 2007,placebo,placebo,58,34
patkar 2007,paroxetine unable to be categorised,ssri,58,38
petzke 2013,placebo,placebo,46,40
petzke 2013,milnacipran high,snri,46,45
pickering 2018,placebo,placebo,29,27
pickering 2018,milnacipran standard,snri,25,24
raskin 2005,placebo,placebo,116,57
raskin 2005,duloxetine standard,snri,116,71
raskin 2005,duloxetine high,snri,116,73
razazian 2014,carbamazepine ,nonad,85,11
razazian 2014,pregabalin ,nonad,86,63
razazian 2014,venlafaxine standard,snri,86,55
rowbotham 2004,placebo,placebo,81,61
rowbotham 2004,venlafaxine low,snri,82,72
rowbotham 2004,venlafaxine high,snri,82,73
rowbotham 2012,placebo,placebo,51,32
rowbotham 2012,duloxetine standard,snri,57,42
rowbotham 2012,abt-894 ,nonad,61,41
rowbotham 2012,abt-894 ,nonad,56,35
rowbotham 2012,abt-894 ,nonad,55,32
russell 2008,placebo,placebo,144,118
russell 2008,duloxetine standard,snri,79,68
russell 2008,duloxetine standard,snri,150,128
russell 2008,duloxetine high,snri,147,132
schukro 2016,placebo,placebo,31,18
schukro 2016,duloxetine high,snri,29,20
shinichi 2016,placebo,placebo,221,132
shinichi 2016,duloxetine standard,snri,234,167
sindrup 2003,placebo,placebo,40,14
sindrup 2003,venlafaxine high,snri,40,20
sindrup 2003,imipramine high,tca,40,20
skljarevski 2009,placebo,placebo,117,69
skljarevski 2009,duloxetine low,snri,59,39
skljarevski 2009,duloxetine standard,snri,116,78
skljarevski 2009,duloxetine high,snri,112,80
skljarevski 2010: 1,placebo,placebo,121,59
skljarevski 2010: 1,duloxetine high,snri,115,72
skljarevski 2010: 2,placebo,placebo,203,112
skljarevski 2010: 2,duloxetine standard,snri,198,123
srinivasan 2021,naltrexone ,nonad,67,8
srinivasan 2021,amitriptyline low,tca,67,36
tesfaye 2013,pregabalin ,nonad,403,232
tesfaye 2013,duloxetine standard,snri,401,223
tetreault 2018,placebo,placebo,20,6
tetreault 2018,duloxetine standard,snri,20,6
trugman 2014,placebo,placebo,111,42
trugman 2014,milnacipran high,snri,210,117
uchio 2018,placebo,placebo,176,98
uchio 2018,duloxetine standard,snri,177,120
urquhart 2018,placebo,placebo,74,14
urquhart 2018,amitriptyline standard,tca,72,13
van ophoven 2004,placebo,placebo,25,22
van ophoven 2004,amitriptyline unable to be categorised,tca,25,5
vollmer 2014,placebo,placebo,120,59
vollmer 2014,duloxetine standard,snri,117,70
wang 2017,placebo,placebo,202,84
wang 2017,duloxetine standard,snri,205,122
watson 1998,amitriptyline unable to be categorised,tca,33,31
watson 1998,nortriptyline unable to be categorised,tca,33,31
wernicke 2006,placebo,placebo,108,79
wernicke 2006,duloxetine standard,snri,114,102
wernicke 2006,duloxetine high,snri,112,96
yasuda 2011,placebo,placebo,167,123
yasuda 2011,duloxetine low,snri,86,72
yasuda 2011,duloxetine standard,snri,86,73
yeephu 2013,placebo,placebo,13,13
yeephu 2013,mirtazapine low,nassa,13,13
yeephu 2013,mirtazapine standard,nassa,14,14
yucel 2005,placebo,placebo,20,11
yucel 2005,venlafaxine low,snri,20,9
yucel 2005,venlafaxine standard,snri,20,14
zabihiyeganeh 2021,cognitive behavioural therapy ,nonad,64,0
zabihiyeganeh 2021,duloxetine standard,snri,64,24